Sep 23, 2026
Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target
Citigroup has initiated coverage of Madrigal Pharmaceuticals (MDGL) with a Buy rating and a price target of $725. This target is significantly higher than the current average analyst price target for MDGL, which stands at $678.18, also reflecting a consensus Buy rating. The article is truncated, suggesting further details are available with a premium subscription.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish